Gsk (GSK) EV to EBITDA (2026)

Gsk (GSK) has 18 years of EV to EBITDA data on file, last reported at 8.22 in Q3 2026.

• For the quarter ending Q3 2026, EV to EBITDA changed N/A year-over-year to 8.22; the trailing twelve-month figure through Sep 2026 stood at 8.22 (changed N/A YoY), and the FY2025 full-year result was 9.53, down 27.42% from the prior year.
• EV to EBITDA was 8.22 for Q3 2026 at Gsk, down from 8.4 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 10.09 in Q1 2022 to a low of 5.84 in Q4 2023.
• A 5-year average of 7.65 and a median of 7.65 in 2026 frame the typical range for EV to EBITDA.
• The largest YoY upside for EV to EBITDA was 128.64% in 2022 against a maximum downside of 36.08% in 2022.
• Gsk's EV to EBITDA stood at 7.2 in 2022, then decreased by 18.95% to 5.84 in 2023, then soared by 40.34% to 8.19 in 2024, then retreated by 16.06% to 6.88 in 2025, then increased by 19.54% to 8.22 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 8.22 in Q3 2026, 8.4 in Q2 2026, and 7.65 in Q1 2026.